YS ON 001

Drug Profile

YS ON 001

Alternative Names: YS-ON-001

Latest Information Update: 27 Oct 2016

Price : $50

At a glance

  • Originator Yisheng Biopharma
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Cancer

Most Recent Events

  • 24 Oct 2016 Clinical trials in Cancer in China (unspecified route)
  • 24 Oct 2016 YS ON 001 receives Orphan Drug status for Hepatocellular cancer in USA
  • 24 Oct 2016 YS ON 001 receives Orphan Drug status for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top